Coronary microcirculatory disease
Conditions
Interventions
Intervention group:Conventional Western medical treatment combined with Compound Danshen Dropping Pills (orally or sublingually, 20 pills per dose, 3 times daily), without concurrent use of other Chin
Control group:Conventional Western medical treatment combined with placebo (orally or sublingually, 20 pills per dose, 3 times daily).
Sponsors
Qilu Hospital, Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with confirmed CMVD angina; 2. 18 years old <= age <= 75 years old, gender is not limited; 3. If the patient has a history of PCI implantation, patients with postoperative coronary stenosis <=50% are required [patients who have completed relatively complete revascularization after PCI and also meet the diagnosis of CMVD (no stenosis greater than 50%) can be enrolled in the trial, and are excluded if they are elective or untreated]; 4. Voluntarily participate in this clinical study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Acute heart failure or acute coronary syndrome; 2. Severe aortic stenosis or coarctation, pulmonary embolism, hypoglycemia (less than 5.5 mmol/L), or severe high/low blood pressure (diastolic blood pressure greater than 210 mmHg or less than 90 mmHg) that does not tolerate exercise loads; 3. Women who are pregnant or breastfeeding; 4. Those with a life expectancy of <2 years due to a combination of malignant tumors or other diseases; 5. Severe lung disease (acute and chronic respiratory failure and moderate or more pulmonary fibrosis, lung damage, etc.); 6. Drugs that dilate blood vessels or temporarily improve myocardial blood supply (e.g., nitrate drugs or ß-blockers, other proprietary Chinese medicines) or drugs that affect cardiac waveforms (e.g., digitalis, antiarrhythmics: amiodarone, etc., phenothiazines, tricyclic, epinephrine, norepinephrine/isopropyl epinephrine, vagotoxin, arsenic agents) taken within 48 hours before the test; 7. Psychosis and others who are unable to cooperate with the study and follow-up; 8. Those who, in the judgment of the investigator, are unsuitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HyperQ check for improvement rate of myocardial ischemia; | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical symptom;Routine electrocardiogram;high-frequency QRS wave; | — |
Countries
China
Contacts
Public ContactYang Ruixue
Qilu Hospital, Shandong University
Outcome results
None listed